8-K: Aimei Health Extends Merger Deadline, Secures $150K Funding

Aimei Health Technology Co., Ltd. has extended its deadline to complete an initial business combination to October 6, 2025, funded by a $150,000 promissory note from its Sponsor and United Hydrogen Group Inc.

Summary

• Aimei Health Technology Co., Ltd. (the Company) extended the period to consummate its initial business combination by one month, from September 6, 2025, to October 6, 2025.
• This marks the tenth of up to 12 permitted extensions under the Company's Amended and Restated Articles of Association.
• An aggregate of $150,000 (the Extension Payment) was deposited into the Company's trust account for its public shareholders to facilitate this extension.
• In connection with the Extension, the Company issued an unsecured promissory note for $150,000 to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the Payees).
• Each Payee contributed $75,000 to fund the Extension Payment.
• The Promissory Note does not bear interest and its principal becomes due and payable upon the consummation of a business combination with United Hydrogen.
• The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company at a price of $10.00 per unit, immediately prior to the business combination closing.
• Each private unit consists of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share.

Sentiment

Score: 5

Explanation: The extension prevents immediate liquidation, which is a positive. However, it is the tenth extension, signaling persistent delays in finalizing a deal. The funding mechanism, while common, highlights continued reliance on the sponsor and potential target, indicating ongoing uncertainty.

Positives

• Secured an additional month (until October 6, 2025) to complete the initial business combination, preventing immediate liquidation.
• The $150,000 Extension Payment was fully funded by the Sponsor and United Hydrogen Group Inc., demonstrating continued support.
• The promissory note issued to fund the extension does not bear interest, avoiding additional debt servicing costs for the Company.

Negatives

• The Company required a tenth extension, indicating persistent challenges or delays in finalizing a business combination.
• Continued reliance on the Sponsor and the potential target (United Hydrogen Group Inc.) for funding extensions suggests limited alternative financing options.
• The ongoing need for extensions may signal a prolonged and uncertain path to completing a de-SPAC transaction.

Risks

• Failure to consummate a business combination by the new Termination Date of October 6, 2025, could lead to the Company's liquidation.
• The promissory note has not been registered under the Securities Act of 1933, restricting its resale without registration or an applicable exemption.
• Potential dilution for existing shareholders if the promissory note is converted into private units by the Payees.
• Events of default for the promissory note include failure to make required payments, bankruptcy, breach of obligations, and unlawfulness of obligations.
• Payees have waived claims against the trust account, meaning the promissory note would only be repaid from non-trust account funds if the business combination is not consummated.

Future Outlook

The Company aims to consummate an initial business combination with United Hydrogen Group Inc. by the new termination date of October 6, 2025. The principal of the promissory note becomes due and payable upon the completion of this business combination.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its deadline to complete a de-SPAC transaction. Extensions are a common occurrence in the SPAC market, often signaling challenges in identifying or closing a suitable target. The involvement of the potential target, United Hydrogen Group Inc., in funding the extension is notable, suggesting a strong commitment to the proposed business combination.

Comparison to Industry Standards

• Many SPACs, such as Gores Holdings VIII, Inc. (GIIX) or Churchill Capital Corp IV (CCIV), have undergone multiple extensions to their business combination deadlines, making this a common practice in the industry.
• The funding mechanism, utilizing a promissory note from the sponsor and a potential target, is a standard method for SPACs to secure additional time, often with conversion rights into the post-combination entity.
• The $10.00 conversion price for private units is consistent with the typical initial public offering price for SPAC units.

Related Party Transactions

• Issuance of an unsecured promissory note for $150,000 to Aimei Health Ltd, which is the Company's Sponsor.
• United Hydrogen Group Inc., the potential business combination target, also contributed $75,000 to the promissory note.

Stakeholder Impact

• Shareholders: Public shareholders benefit from the extension as it prevents immediate liquidation and provides more time for a business combination to materialize. However, continued delays and potential dilution from note conversion are concerns.
• Sponsor (Aimei Health Ltd): Provides funding to extend the SPAC's life, maintaining its investment and potential for a successful business combination.
• United Hydrogen Group Inc. (Potential Target): Contributes funding, indicating commitment to the proposed business combination and ensuring the SPAC remains active to complete the deal.

Next Steps

• Consummate the initial business combination with United Hydrogen Group Inc. by October 6, 2025.
• Payees may exercise their right to convert the promissory note into private units prior to the business combination closing.

Key Dates

Recommendation

The extension prevents immediate liquidation, which is a positive for current shareholders. However, this is the tenth extension, indicating significant delays in closing a business combination. While the funding from the sponsor and potential target shows commitment, the prolonged process introduces uncertainty. Investors should hold to see if the business combination with United Hydrogen Group Inc. is successfully completed by the new deadline.

Keywords

Aimei Health Technology, AFJK, SPAC, business combination, extension, promissory note, United Hydrogen Group, trust account, merger deadline, Nasdaq